Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer

Erika Rijavec, Carlo Genova, Giulia Barletta, Federica Biello, Giovanni Rossi, Marco Tagliamento, Maria Giovanna Dal Bello, Simona Coco, Irene Vanni, Simona Boccardo, Angela Alama, Francesco Grossi

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: Fibroblast growth factor receptor (FGFR) due to its central role in regulating cell survival, is a promising target for cancer therapeutics. Dysregulation of the FGFR pathway has been observed in several malignancies, including non-small cell lung cancer (NSCLC) particularly in patients with squamous histology. Areas covered: The aim of this article is to review the most relevant findings of clinical trials investigating drugs targeting FGFR pathway: such as FGFR tyrosine kinase inhibitors (TKIs), FGFR monoclonal antibodies and FGF ligand traps in NSCLC patients. Expert opinion: At present, clinical activity of drugs targeting FGFR in NSCLC is disappointing. Further studies are needed in order to better identify patients who might benefit from these drugs and to clarify the mechanisms of resistance to these compounds.

Original languageEnglish
Pages (from-to)551-561
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number5
DOIs
Publication statusPublished - May 4 2017

Keywords

  • FGF
  • FGFR
  • FGFR TKI
  • NSCLC

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this